Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor — Stella

Home/Gastrointestinal Stromal Tumors/

View on ClinicalTrials.gov

Recruiting

Back to Gastrointestinal Stromal Tumors trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

South Korea

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul

Key details

Phase

Safety & dosing

Sponsor

Asan Medical Center

Enrollment target

~48 participants

Started

September 2023

Primary completion

August 2027

Age range

20 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.